---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-005922"
form_type: "8-K"
ticker: "ANIK"
cik: "0000898437"
company_name: "Anika Therapeutics, Inc."
filed_at: "2024-10-31T23:59:59+00:00"
generated_at: "2026-05-30T07:52:59.908923+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Anika Therapeutics completes sale of Arthrosurface for $10M; plans to divest Parcus Medical

## Summary
- Sold Arthrosurface to Phoenix Brio for $7M note plus up to $3M contingent consideration based on sales performance.
- Announced intention to sell Parcus Medical sports medicine business as part of strategic review.
- Focus shifts to core hyaluronic acid (HA) products and Regenerative Solutions, targeting $4B global market.
- Piper Sandler serving as exclusive financial advisor for both the Arthrosurface sale and potential Parcus divestiture.

## SEC filing metadata
- accession: 0001171843-24-005922
- form_type: 8-K
- ticker: ANIK
- cik: 0000898437
- company_name: Anika Therapeutics, Inc.
- filed_at: 2024-10-31T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/898437/000117184324005922/0001171843-24-005922-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/898437/000117184324005922/f8k_103024.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-005922
- JSON: https://secwatch.observer/filing/0001171843-24-005922.json
- Plain text: https://secwatch.observer/filing/0001171843-24-005922.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.